Related Experiment Videos
Acute mucocutaneous toxicity following high-dose hydroxyurea
1Department of Hematology, Odense University Hospital, Denmark.
Cancer Chemotherapy and Pharmacology
|January 1, 1993
Summary
High-dose hydroxyurea in acute myeloid leukemia patients caused severe mucocutaneous toxicity, including stomatitis and skin changes. This suggests skin and mouth side effects, not myelosuppression, may limit hydroxyurea dosage.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Acute myeloid leukemia (AML) is a serious hematologic malignancy.
- Hydroxyurea is used in various conditions, but its high-dose effects require careful monitoring.
- Understanding drug toxicity is crucial for safe and effective cancer treatment.
Observation:
- Three patients with advanced AML received daily oral high-dose hydroxyurea (10 g/day for 8-10 days).
- All patients experienced severe acute stomatitis.
- Two patients developed unique cutaneous toxicity: sore palms and soles with violet erythema, edema, and subsequent hyperpigmentation.
Findings:
- Sustained high daily doses of hydroxyurea can lead to pronounced acute mucocutaneous toxicity.
- The observed toxicity included severe stomatitis and a distinct palm/sole syndrome.
- Myelosuppression might not be the primary dose-limiting factor for hydroxyurea.
Implications:
- Hydroxyurea's dose-limiting toxicity may be mucocutaneous rather than hematologic.
- Clinical monitoring for stomatitis and skin reactions is essential in patients receiving high-dose hydroxyurea.
- This finding could inform treatment protocols and patient management strategies for AML and other conditions treated with hydroxyurea.